Component
Human plasma TMAO after oral ALCAR
Human plasma TMAO after oral ALCAR
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Oral ALCAR markedly increased plasma TMAO in the 2025 healthy-volunteer study.
Experimental context and source evidence
- evidence_access
- Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
- experimental_contrast
- {"intervention": "Single nominal 1.5-g ALCAR dose", "comparator": "Predose baseline", "endpoint": "Oral ALCAR markedly increased plasma TMAO in the 2025 healthy-volunteer study.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- Single nominal 1.5-g ALCAR; plasma and urine collection over 48 h.
- interpretation_status
- Source-derived curation with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
- plain_language
- Oral ALCAR markedly increased plasma TMAO in the 2025 healthy-volunteer study.
- primary_references
- Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism. | https://pubmed.ncbi.nlm.nih.gov/41243468/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12700042/ | https://doi.org/10.1002/mnfr.70316
- source_locator
- Reviewed reference pk-tmao; Median TMAO increased approximately 2.2 to 47 micromolar; adjusted exposure was comparable to L-carnitine. The acetyl group did not prevent this metabolite signal. Cardiovascular events were not measured.
Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 128–134
AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Single nominal 1.5-g ALCAR; plasma and urine collection over 48 h. · Recorded from source · Recorded from source
### pk-tmao Oral ALCAR markedly increased plasma TMAO in the 2025 healthy-volunteer study. Median TMAO increased approximately 2.2 to 47 micromolar; adjusted exposure was comparable to L-carnitine. The acetyl group did not prevent this metabolite signal. Cardiovascular events were not measured. Model and exposure: Single nominal 1.5-g ALCAR; plasma and urine collection over 48 h. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism. | 2025 | https://pubmed.ncbi.nlm.nih.gov/41243468/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12700042/ | https://doi.org/10.1002/mnfr.70316 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.